Article

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Hepatology (Impact Factor: 11.19). 06/2008; 47(6):1884-93. DOI: 10.1002/hep.22319
Source: PubMed

ABSTRACT Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks). Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 microg/week) and ribavirin (1000-1200 mg/day) with a 24-week follow-up. The primary endpoint was a sustained virological response (SVR; seronegative for HCV RNA at 24-week follow-up). Overall, the 48-week arm had a significantly higher SVR rate (79%) than the 24-week arm (59%, P = 0.002). For 87 (43.5%) patients with an RVR, the 24-week arm had a lower SVR rate [88.9%; 95% confidence interval (CI): 80%-98%] than the 48-week arm (100%, P = 0.056). For 52 patients with low baseline viremia (<400,000 IU/mL) and an RVR, the 24-week arm had rates (CI) of relapse and SVR of 3.6% (-3%-11%) and 96.4% (89%-103%), respectively, which were comparable to those of the 48-week arm (0% and 100%) with difference (CI) of 3.6% (-7.2%-6.6%) and -3.6% (-14.3% to -0.6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight-based exposure of ribavirin, and baseline viral load. CONCLUSION: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of peginterferon/ribavirin even if they attain an RVR. Both 24 and 48 weeks of therapy can achieve high SVR rates (>96%) in HCV-1 patients with low viral loads and an RVR.

Full-text

Available from: Ming-Lung Yu, Apr 20, 2015
0 Followers
 · 
109 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective This study aimed to investigate the association of interleukin 28B (IL28B) single nucleotide polymorphisms (SNPs) with sustained response (SVR) in Chinese Han patients with chronic hepatitis C (CHC) and to analysz the correlations between IL28B SNPs and their demographic, virological and clinical characteristics.Methods Altogether 631 Chinese Han individuals including 297 CHC patients treated with pegylated interferon α plus ribavirin, 14 spontaneous hepatitis C virus (HCV) responders and 320 healthy controls were enrolled in the study. Two main SNPs of IL28B, rs12979860 and rs8099917, were genotyped using SNaPshot Multiplex assay. Associations between IL28B and treatment outcomes as well as demographic, virological and clinical characteristics of the patients were assessed by multivariate logistic regression.ResultsThe proportion of individuals with rs12979860 CC genotype or rs8099917 TT genotype was similar in healthy controls and CHC patients, although all spontaneous responders presented with these two genotypes. Patients with IL28B genotypes had a significantly high rate of rapid virological response (RVR) and SVR. Multivariate analysis revealed that IL28B SNP rs12979860 CC genotype (odds ratio [OR] 14.986, 95% confidence interval (CI) 5.056–44.422, P < 0.001), age <40 years (OR 0.239, 95% CI 0.600–0.954, P = 0.043) and non-G1 genotype (OR 0.122, 95% CI 0.015–0.985, P = 0.048) were independent predictors for SVR. And rs12979860 CC genotype (OR 25.754, 95% CI 3.315–200.101, P = 0.002) and rs8099917 TT genotype (OR 15.740, 95% CI 2.101–118.07, P < 0.001) were the predictors for RVR. rs12979860 CC genotype and rs8099917 TT genotype were more prevalent in patients with non-G1 genotype than those with G1 genotype.ConclusionsIL-28B rs12979860 CC genotype is a significant predictor for SVR and RVR in Chinese Han patients with CHC. Non-G1 HCV genotype is associated with favorable IL28B genotypes.
    Journal of Digestive Diseases 10/2014; 16(2). DOI:10.1111/1751-2980.12202 · 1.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To elucidate the association between antiviral therapy and extrahepatic outcomes in individuals infected with HCV.
    Gut 11/2014; 64(3). DOI:10.1136/gutjnl-2014-308163 · 13.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Our goal was to systematically and quantitatively assess treatment response between Asian patients with hepatitis C virus genotype 6 (HCV-6) and hepatitis C virus genotype 1 (HCV-1) treated for 48 weeks with pegylated interferon and ribavirin. Methods: We performed a literature search in MEDLINE and EMBASE for 'genotype 6' in August 2013. Additional abstracts from major international scientific conferences from 2012 to 2013 were reviewed. Studies included were original articles with ≥10 treatment-naïve Asian HCV-6 patients. Exclusion criteria were coinfections with hepatitis B virus, HIV and/or other liver diseases. Heterogeneity was defined as a Cochrane Q test with a p value of 0.10 and an I(2) statistic of >50%. Results of a random-effects model are reported. Results: A total of 1,046 (503 HCV-6; 543 HCV-1) patients from 12 studies were included in the analysis. The pooled sustained virologic response (SVR) rate was 80.2% (95% CI 74.3-85.0, Q statistic = 20.87, p < 0.035; I(2) = 47.3%) for HCV-6 and 62.5% (95% CI 41.9-79.4, Q statistic = 52.41, p < 0.001; I(2) = 92.37) for HCV-1 patients. HCV-6 patients had a significantly higher SVR rate compared to HCV-1 patients (odds ratio 2.73, 95% CI 1.69-4.41, p < 0.001). Approximately one fourth of patients without early virologic response (EVR) achieved SVR, regardless of genotype (HCV-1, n = 6/23; HCV-6, n = 4/21). Conclusions: Asian patients with HCV-6 can expect higher SVR rates (∼80%) than HCV-1 patients (∼63%). EVR as a stopping rule is less clear in Asian patients with HCV-6 and HCV-1. © 2015 S. Karger AG, Basel.
    Intervirology 01/2015; 58(1):27-34. DOI:10.1159/000369097 · 1.77 Impact Factor